Ticagrelor Market Growth and Restrain Factors Analysis Report 2022
Ticagrelor drugs are primarily used in the treatment of
cardiovascular disorders and other heart conditions, including diseased
vessels, structural problems, and blood clots. In acute coronary syndrome, the
combination of ticagrelor and aspirin is reported to have reduced the rate of
vascular deaths and myocardial infarctions. As a result, ticagrelor drugs
garner a vast market prominence and its market witnesses pervasive growth.
Increasing occurrences of cardiovascular disorders is a
dominant driving force behind the growth of the market. Besides, the rise in
the geriatric population has a direct impact on the growth of the market.
According to a leading research firm - Market Research Future (MRFR), the
global Ticagrelor
market is poised to register a valuation of USD 2554.39 MN by 2027. In its
newly published study report, MRFR also asserts that the market would post a
CAGR of 9% throughout the review period (2017 – 2027).
Additionally, increasing occurrences of obesity are
encouraging the market demand, fuelling the cardiovascular patient pool. Also,
growing numbers of drug manufacturers are driving the growth of the market,
bringing novel medications in the market. Substantial investments transpired
into R&D activities driven by improving economic conditions provide impetus
to the growth of the market.
Conversely, factors impeding the growth of the market,
include patent expiries and side effects of Ticagrelor such as bleeding that
can sometimes go worst, leading to death. Nevertheless, factors such as
substantial technological strides that increase the efficacies of Ticagrelors
would support market growth, increasing market demand.
Major Players:
Players leading the global Ticagrelor market include
Eli Lilly, AstraZeneca, Boehringer, Pfizer, Ingelheim, Amgen, Roche, Merck,
GSK, Ingelheim Pfizer, Alexion, Boehringer, and Amgen, among others.
Get Sample Report: https://www.marketresearchfuture.com/sample_request/820
Global Ticagrelor Market – Segments
The report is segmented into five market dynamics to widen
the scope of understanding,
By Dosage: 90 Mg and 60 Mg.
By Route of Administration: Oral and Nasogastric
Tube.
By Route of Application: Acute Coronary Syndrome,
Heart Surgeries, Angioplasty, Stent Placement, and Coronary Artery Bypass
Graft, among others.
By End-user: Hospitals & Clinics and Ambulatory
Centers, among others.
By Regions: Europe, North America, Asia Pacific, and
the Rest-of-the-World.
Global Ticagrelor Market – Regional Analysis
North America leads the global Ticagrelor market with the
largest market share. Heading with the rising geriatric population that is
highly prone to degenerative diseases and prevalent chronic diseases, the
region is estimated to retain its dominance throughout the forecast period.
Additionally, the presence of a well-developed healthcare sector, alongside,
the high per capita healthcare expenditures and well-spread awareness drive the
regional market growth.
Growing markets in the US and Canada backed by the presence
of prominent market players, positively impact the growth of the Ticagrelor
market in the region. Furthermore, increasing diagnosis and therapeutics would
support the market to create a significant revenue pocket during the assessment
period (2017-2027).
The Ticagrelor market in the European region accounts for
the second-largest market, globally. The rising patient population of strokes
& cardiovascular disorders and the introduction of advanced &
integrated treatment options are expected to boost the regional market growth.
Moreover, factors such as favorable government support for
researches on antiplatelets, availability of advanced treatment facilities, and
increasing healthcare expenditure, foster the growth of the market in the
region. The UK, backed by its sizeable Ticagrelor market and Germany with its
vast medical technology and pharmaceutical industry, contribute to the growth
of the regional market, significantly.
The Asia Pacific Ticagrelor market is rapidly emerging as a
promising market globally. Factors like increasing per capita disposable income
and government initiatives to enhance the quality of healthcare drive the
regional market growth. Moreover, the burgeoning pharmaceutical industry in
this region is predominantly influencing the growth of the APAC Ticagrelor
market.
Additionally, spreading awareness towards the disorder and
the availability of novel treatment procedure to manage the condition influence
the growth of the regional market, positively. Furthermore, the rising
prevalence of cardiovascular diseases led by the changing lifestyles alongside,
the continually rising healthcare expenditures and favorable government
policies substantiate the market growth in the APAC region.
Global Ticagrelor Market – Competitive Analysis
Fiercely competitive, the Ticagrelor market appears to be
fragmented due to the presence of many players. Large and small players
alongside, the new entrants form a competitive landscape. They try to gain a
substantial market share through strategic initiatives such as mergers &
acquisitions, expansion, collaboration, and product/ technology launch.
Industry, Innovation & Related News
September 02, 2019 –--- Strs Ohio (the US), a leading
global institutional investor announced the acquisition of a new stake in Phase
Bio Pharmaceuticals Inc. (the US), a clinical-stage biopharmaceutical company.
PhaseBio focuses on the development and commercialization of novel therapies
and drugs, such as a reversal agent for the antiplatelet drug ticagrelor. The
institutional investor acquired 3,700 shares of the company’s stock, valued at
approximately USD 48,000.
Access Report Details @ https://www.marketresearchfuture.com/reports/ticagrelor-market-820
Related Reports: U.S.
Direct Anterior Approach Market Research Report –Global Forecast to 2027
Magnetic
Resonance Imaging (MRI) Market Research Report – Forecast to 2027
Endometrial
Cancer Market Research Report – Forecast to 2027
Digital
Wound Measurement Devices Market Research Report – Forecast to 2027
Flow
Cytometry Market Research Report – Forecast to 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment